# A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients

> **NCT00515437** · PHASE2 · COMPLETED · sponsor: **Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC** · enrollment: 54 (actual)

## Conditions studied

- Drooling

## Interventions

- **BIOLOGICAL:** Botulinum Toxin Type B (Myobloc)
- **BIOLOGICAL:** Matched placebo to Myobloc

## Key facts

- **NCT ID:** NCT00515437
- **Lead sponsor:** Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-06
- **Final completion:** 2008-09
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515437, "A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00515437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*